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ABSTRACT - Objective: To identify clinical and immunological markers associated with HTLV-I associated
m y e l o p a t h y / t ropical spastic paraparesis (HAM/TSP). Method: 237 HTLV-I infected individuals were clini-
cally assessed. They were classified according to the Expanded Disability Status Scale (EDSS) and Osame’s
Motor Disability Score (OMDS). Cytokine levels were determined in HTLV-I seropositive individuals. R e s u l t s :
37 patients had HAM/TSP. There was a correlation between the degrees of disability assessed by both scales.
T h e re was also a correlation between the duration of HAM/TSP and the severity of disability assessed by
either EDSS or OMDS. Higher levels of IFN-γ w e re detected in unstimulated peripheral blood mononuclear
cells (PBMC) from HAM/TSP patients as compared with HTLV-I carriers. Conclusion: This study shows the
validity of the neurological scales to classify the degree of neurological disability in HTLV-I carriers and sug-
gests a pro g ressive behavior of HAM/TSP. This study also shows that IFN-γ in PBMC supernatants are mark-
ers of HAM/TSP. 
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Associação de citocinas, incapacidade neurológica e duração da doença em pacientes com
mielopatia associada ao HTLV-I/paraparesia espástica tropical (MAH/PET)
RESUMO - O b j e t i v o: Identificar marc a d o res clínicos e imunológicos associados com a mielopatia associada
ao HTLV- I / p a r a p a resia espástica tropical (MAH/PET). Método: 237 indivíduos infectados pelo HTLV-I foram
clinicamente avaliados. Eles foram classificados de acordo com a escala expandida do estado de incapaci-
dade de Kurtzke (EDSS) e escala de incapacidade motora de Osame (OMDS). Níveis de citocinas foram
d e t e rminados nos indivíduos. Resultados: 37 pacientes tinham MAH/PET. Houve correlação entre os graus
de incapacidade pelas escalas. Houve também correlação entre a duração da MAH/PET e o grau da inca-
pacidade pelas escalas. Níveis elevados de IFN-γ foram detectados em células mononucleares de sangue
periférico (CMSP) não estimuladas de pacientes com MAH/PET quando comparados com indivíduos HTLV-
I positivos assintomáticos. Conclusão: Os dados demonstram a validade das escalas neurológicas para
classificar o grau de incapacidade neurológica em port a d o res do HTLV-I e sugerem o comportamento pro-
g ressivo da MAH/PET. Este estudo também demonstra que os níveis de IFN-γ em sobrenadante de CMSP
são marcadores da MAH/PET. 
PA L AV R A S - C H AVE: v í rus 1 linfotrópico T humano, doenças do sistema nervoso, citocinas, incapacidade neu-
rológica.
Human T cell lymphotropic virus type I (HTLV-I) is
an exogenous human re t ro v i rus associated with adult
T cell leukemia and a pro g ressive neurological dis-
ease named HTLV-I-associated myelopathy/tro p i c a l
spastic paraparesis (HAM/TSP)1 - 3. About 20 million
people are infected worldwide with endemic foci in
S o u t h e rn Japan, the Caribbean, Central and South
America, Africa4. However, the vast majority of these
individuals are clinically asymptomatic and less than
5% of them develop HAM/TSP1. The prevalence of
H T LV-I infection is high in Brazil, particularly in the
city of Salvador, where 1.35% of blood donors are
infected5. 
How HTLV-I causes this disease is not completely
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understood, although virus-host immunological inter-
actions have been suggested to play a role in the
pathogenesis of the disord e r2. The immunological
response in HTLV-I infection is characterized by spon-
taneous T-cell proliferation with increasing secre t i o n
of interleukin (IL)-2 and expression of the IL-2 re c e p-
t o r6. Abnormalities in this response have been shown
in patients with HAM/TSP compared to HTLV-I asymp-
tomatic individuals, including elevated levels of
cytokines such as tumor necrosis factor-α ( T N F -α), IL-
6, and IL-2 in sera and cerebrospinal fluid (CSF)6-9. 
The major aim of the current study is to evaluate
the association among cytokines, neurological dis-
ability, and disease duration in HAM/TSP patients. 
METHOD
Patients – Two hundred and thirty-seven patients
re f e rred from blood banks or from neurological clinics in
S a l v a d o r, Brazil, were admitted to the HTLV-I Multidiscipli-
n a ry Outpatient Clinic of Hospital Universitário Pro f e s s o r
E d g a rd Santos, Federal University of Bahia, Brazil, fro m
September 2000 to August 2001. In all cases the diagnosis
was established by ELISA (Cambridge Biotech Corp., Wo r-
ceste, MA, U.S.A) and confirmed by Western blot analysis,
distinguishing HTLV-I from HTLV-II (HTLV blot 2.4, Genelab,
S i n g a p o re). These subjects were assessed using a standard-
ized questionnaire to determine the initial clinical mani-
festations of HTLV-I infection. These patients were then
submitted to a complete clinical and neurological exami-
nation to evaluate if they had signs of HAM/TSP. Thirt y - s e v-
en patients with HAM/TSP, according to consensus guide-
l i n e s1 0, were identified. Neurological disability was deter-
mined based upon Osame’s Motor Disability Score (OMDS)1 1
and Extended Disability Status Scale (EDSS)12 by the assist-
ing neurologist (André Muniz, MD). HTLV-I associated
myelopathy was clinically defined as EDSS ≥3 and OMDS
≥1 for this study. Thirty-eight asymptomatic HTLV-I posi-
tive individuals served as the control group for the immuno-
logical studies. All asymptomatic subjects scored no points
according to both scales. 
All eligible subjects or minors’ parents/guardians gave
written informed consent to participate and the study was
a p p roved by the Hospital Universitário Professor Edgard
Santos Ethical Committee.
Cytokine determination – The levels of interf e ro n -γ,
T N F -α, IL-5, and IL-10 were measured in culture supern a t a n t s
of peripheral blood mononuclear cells (PBMC) from 21
patients with HAM/TSP and 38 HTLV-I asymptomatic carri-
ers. Cytokine determination was perf o rmed in a seven-day
period after neurological evaluation. Immunological stud-
ies were not perf o rmed in 16 patients with HAM/TSP
because they were in use or had used i mmunosupre s s o r s
or immunomodulators in the previous 90 days of the enro l l-
ment visit. Briefly, PBMC, isolated from heparinized venous
blood by lymphocyte isolation medium, were adjusted to
3 x 1 06 cells per milliliter in RPMI 1640 plus 10% heat inac-
tivated human serum AB Rh+. The cells were incubated at
37ºC in 5% CO2 a t m o s p h e re for 72 hours without stimulus.
S u p e rnatants were collected and stored at –20ºC until use.
I n t e rf e ro n -γ, TNF-α, IL-5, and IL-10 levels were measure d
by ELISA sandwich technique following instru c t i o n s
described by the manufactures (R & D system, Minneapolis,
MN, USA). The results were expressed as picograms per mil-
liliter based upon a standard curve generated using re c o m-
binant cytokines. To measure IFN-γ levels, the samples fro m
HAM/TSP patients were diluted 5X because the levels were
above the highest point of the standard curve.
Statistical analysis – Collected data w ere inserted in a
data bank and analyzed with the help of a statistical pack-
age (SPSS version 9.0). The means and standard deviations
(SD) of demographic data and cytokine levels were calcu-
lated for all the 21 patients with HAM/TSP selected for
immunological evaluation, as well as for 38 HTLV-I asymp-
tomatic carriers. Correlation among the cytokines levels,
n e u rological scales, and time of disease evolution were
made using the Spearm a n ’s correlation. Diff e re n c e s
between the two groups were evaluated by a non-para-
metric Mann-Whitney U Test. A statistical significance was
considered if p<0.05.
RESULTS
F rom the 237 HTLV-I positive individuals 51.1%
w e re men. The overall mean age was 43±13 years.
The 37 patients with HAM/TSP (15 men and 22
women) had 53±14 years mean age. The mean age
of the 38 HTLV-I asymptomatic carriers (26 men and
12 women) was 42±11 years. The median EDSS of the
37 HAM/TSP patients was 4.0, ranging from 3.0 to
9.5. These patients also presented an OMDS ranging
f rom 1 to 12 with a median of 4.0. The patients
excluded from the immunological evaluation had a
median EDSS of 4.0, ranging from 3.0 to 9.0, and a
median OMDS of 5.0, ranging from 2 to 11.
All HAM/TSP patients presented pyramidal dys-
function as assessed by EDSS. Eighty-one percent had
bladder dysfunction, 62% presented bowel impair-
ment, 56% presented sensory alteration, and 51%
complained of decreased libido or erectile dysfunc-
tion, or both. There was a high concordance between
the neurological disability scores assessed by both
scales (Fig 1). The patients in initial stages of neuro-
logical dysfunction with low grade of motor disabil-
ity (OMDS=1) presented bladder compromise in 64%,
bowel movement impairment in 33%, and sensory
alterations in 11%.
T h e re was also a correlation between the neuro-
logical disability evaluated by EDSS and duration of
disease, as well as between the disability evaluated
by OMDS and disease duration (Fig 2). Both gro u p s
of HAM/TSP patients and HTLV-I asymptomatic car-
riers had a high variability in IFN-γ levels (Fig 3).
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The mean (±SD) IFN-γ levels in myelopathy patients
(4,456 ± 2,815 pg/ml, range: 375 to 10,750 pg/ml) was
higher than IFN-γ levels observed in asymptomatic
c a rriers (1,277±1,356 pg/ml, range: 0 to 6,995 pg/ml).
To observe if these IFN-γ levels in PBMC did not re f l e c t
a transient situation, the levels were measured 2
months after the first evaluation in 05 HAM/TSP
patients and in 05 asymptomatic HTLV-I carriers. No
significant diff e rence was observed between the
mean (±SD) IFN-γ levels from the first to the second
evaluation either in asymptomatic HTLV-I individu-
als (1,053±643 pg/ml and 1,403±896 pg/ml, re s p e c-
tively in the first and second evaluations; p=0.54) or
in HAM/TSP patients (6,827±3,847 pg/ml and
6 , 8 4 6±1,374 pg/ml; p=0.69). No significant diff e re n c e s
in other cytokine levels were observed between
HAM/TSP patients and asymptomatic HTLV-I carr i e r s :
T N F -α levels (335±315 pg/ml versus 244±365 pg/ml;
p=0.202), IL-5 levels (180±141 pg/ml versus 163±2 2 8
Fig 1. Correlation between the degree of neurological disabil -
ity assessed by EDSS and OMDS of HAM/TSP patients (n=37);
(rs=0.857; p<0.001).
Fig 3. Interf e ro n -γ levels in unstimulated peripheral blood
mononuclear cells from HAM/TSP patients (n=21) as compare d
with asymptomatic HTLV-I positive individuals (n=38), p<0.0001;
Mann Whitney U test.
Fig 2. A) Correlation between the time of the initial signs of
HAM/TSP and the degree of neurological disability assessed by
EDSS from HAM/TSP patients (n=36); (rs=0.511; p=0.001). B)
Correlation between the time of the initial signs of HAM/TSP
and the degree of neurological disability assessed by OMDS
from HAM/TSP patients (n=36); (rs=0.406; p=0.014). 
Table 1. Correlation between cytokines, evaluation scales,
and duration of disease in HAM/TSP patients.
Cytokines Nº of cases Spearman’s r
IFN-γ / IL-5 21 / 15 0.560a
IFN-γ / IL-10 21 / 21 0.087
IFN-γ / TNF-α 21 / 17 0.304
TNF-α / IL-5 17 / 15 –0.043
TNF-α / IL-10 17 / 21 0.563a
IL-5 / IL-10 21 / 15 0.213
ap < 0.05.
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pg/ml; p=0.113), and IL-10 levels (76±113 pg/ml ver-
sus 90±108 pg/ml; p=0.670).
We observed a correlation between IFN-γ and IL-
5 levels and between TNF-α and IL-10 levels in
HAM/TSP patients (Table 1). There was no significant
c o rrelation between IFN-γ, TNF-α, IL-5, IL-10 levels
and the neurological disability or with the duration
of illness in HAM/TSP patients.
DISCUSSION
The present study shows that although there is a
similar pro p o rtion of males and females infected by
H T LV-I, the frequency of females with HAM/TSP is
higher than males (OR 3.178, 95% CI 1.23 – 8.20; p=
0.03). The HAM/TSP group present a high fre q u e n c y
of sensory alterations. The initial symptoms of
HAM/TSP observed were bladder compromise, bow-
el movement impairment, and sensory alterations.
Although these symptoms are unspecific, they should
call the attention of clinicians to suspect and inves-
tigate HTLV-I infection and perf o rm specialized neu-
rological evaluation. The diagnosis might re q u i re a
g reat degree of suspiciousness, especially in re g i o n s
where HTLV-I infection is not endemic.
EDSS and OMDS are two scales broadly used pre-
senting a good correlation with severity1 0 , 1 3. We
extended this finding showing there is a positive cor-
relation between the degrees of neurological disabil-
ity assessed by the EDSS and OMDS. We also observ e d
a positive correlation between each one of the func-
tional incapacity scales and disease duration.
Although this is a cross-sectional study, our data sug-
gest a pro g ressive worsening over time. However, it
does not determine whether the disease pro g re s s i o n
was linear or fluctuating.
Despite many studies evaluating the HTLV- I
immunological response in patients with HAM/TSP,
few studies perf o rmed comparative analysis of the
immunological response between HAM/TSP patients
and asymptomatic HTLV-I carriers, as well as looked
for the immune response in patients in diff e re n t
d e g rees of neurological disability and diff e rent peri-
ods of disease1 4. The large number of HTLV-I infect-
ed individuals followed at the HTLV-I Multidisciplinary
Outpatient Clinic of the University Hospital in
S a l v a d o r, has allowed, based upon neurological exam-
ination, the enrollment and evaluation of HTLV-I car-
riers and HAM/TSP patients. 
This immunological evaluation shows that unstim-
ulated PBMC from patients with HAM/TSP secre t e
higher amounts of cytokines such as IFN-γ and TNF-
α as compared to HTLV-I asymptomatic carr i e r s .
Although IFN-γ synthesis was higher in patients with
H A M / T S P, these responses were quite variable and in
some asymptomatic carriers the IFN-γ p roduction was
similar to that found in patients with HAM/TSP, as
also demonstrated in a recent publication15. 
T h e re was no correlation between neuro l o g i c a l
disability and cytokine levels; on the other hand,
t h e re were elevated levels of helper T cell 1 (Th1)
cytokines in PBMC with different degrees of neuro-
logical disability, suggesting a state of constant
i n f l a m m a t o ry activity (steady-state). However, there
was a trend toward an inverse correlation of IFN-,
TNF-, IL-10, and IL-5 levels in unstimulated PBMC with
time of illness duration, showing a slight decrease of
inflammatory response over time.
Among the evaluated cytokines, there was a tre n d
of a positive correlation between IFN-γ and TNF-α,
Th1 profile cytokines, as well as between IFN-γ a n d
IL-5, and between TNF-α and IL-10. We have pre v i-
ously shown that a positive correlation between type
1 and type 2 cytokines may occur in HTLV-I carriers6.
H e rein we show this correlation also occurs in
HAM/TSP patients. These correlations may reflect an
attempt to modulate the pro i n f l a m m a t o ry re s p o n s e1 6,
once IL-10 is the main down re g u l a t o ry cytokine of
I F N -γ p ro d u c t i o n1 7. Interleukin-10 has a suppre s s i v e
e ffect over macrophages and T-cells cytokine pro d u c-
tion. It is also able to inhibit T-cells proliferation and
to suppress macrophages activation mediated by IFN-
γ18, and suppresses TNF-α synthesis19. 
In combination, these results suggest a marked
type 1 immune response with elevated IFN-γ as a
marker of disease pro g ression. However, in patients
with already established neurological disease there
is no association between severity of disease, cytokine
levels, and illness duration. Since cellular activation
and cytokine production are directly involved in the
pathogenesis of HAM/TSP8 , 2 0 - 2 3, prospective studies
a re necessary to trace the disease natural course.
H T LV-I asymptomatic carriers with high pro d u c t i o n
of IFN-γ should be conducted for a follow-up study
to observe illness pro g ression and assess early signs
of neurological dysfunction as bladder compro m i s e ,
bowel movement impairment, and sensory alter-
ations.
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